Oncothyreon Shares Up on News of Lung Cancer Trial
Shares of Oncothyreon rose on 10 December following the announcement that its partner Merck had started a late-stage study on Stimuvas as a potential lung cancer treatment. The Phase III trial, named Inspire, will focus on Asian patients with advanced non-small cell lung cancer.
Shares of Oncothyreon rose on 10 December following the announcement that its partner Merck had started a late-stage study on Stimuvas as a potential lung cancer treatment.
The Phase III trial, named Inspire, will focus on Asian patients with advanced non-small cell lung cancer.
It will enroll about 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.